Do analysts prefer DRCT or TRAW?

Traws Pharma has a consensus price target of $1.00, suggesting a potential upside of 63.67%. Given Traws Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Traws Pharma is more favorable than Direct Digital. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Direct Digital 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Traws Pharma 2 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.60

Is TRAW or PDSB more profitable?

PDS Biotechnology's return on equity of -346.02% beat Traws Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Traws Pharma N/A -913.18% -133.88% PDS Biotechnology N/A -346.02% -102.36%

Is CRVO or TRAW more profitable?

Traws Pharma has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. CervoMed's return on equity of -136.08% beat Traws Pharma's return on equity. Company Net Margins Return on Equity Return on Assets CervoMed -672.80% -136.08% -112.62% Traws Pharma N/A -913.18% -133.88%

Is TRAW or ACTU more profitable?

Actuate Therapeutics' return on equity of -430.93% beat Traws Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Traws Pharma N/A -913.18% -133.88% Actuate Therapeutics N/A -430.93% -180.86%

Traws Pharma (TRAW) Competitors

$0.61 +0.00 (+0.38%)

As of 03:48 PM Eastern

Compare

TRAW vs. DRCT, SLGL, PDSB, CRVO, and ACTU

Should you buy Traws Pharma stock or one of its competitors? MarketBeat compares Traws Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Traws Pharma include Direct Digital (DRCT), Sol-Gel Technologies (SLGL), PDS Biotechnology (PDSB), CervoMed (CRVO), and Actuate Therapeutics (ACTU).

How does Traws Pharma compare to Direct Digital?

Direct Digital (NASDAQ:DRCT) and Traws Pharma (NASDAQ:TRAW) are related small-cap companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.

Traws Pharma has lower revenue, but higher earnings than Direct Digital. Traws Pharma is trading at a lower price-to-earnings ratio than Direct Digital, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Direct Digital	$34.69M	0.06	-$18.95M	-$201.62	N/A
Traws Pharma	$2.79M	3.32	$9.17M	-$1.69	N/A

In the previous week, Direct Digital had 1 more articles in the media than Traws Pharma. MarketBeat recorded 1 mentions for Direct Digital and 0 mentions for Traws Pharma. Direct Digital's average media sentiment score of 0.59 beat Traws Pharma's score of 0.00 indicating that Direct Digital is being referred to more favorably in the media.

Company	Overall Sentiment
Direct Digital	Positive
Traws Pharma	Neutral

Traws Pharma has a net margin of 0.00% compared to Direct Digital's net margin of -65.75%. Direct Digital's return on equity of 0.00% beat Traws Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Direct Digital	-65.75%	N/A	-59.57%
Traws Pharma	N/A	-913.18%	-133.88%

Direct Digital has a beta of 5.32, meaning that its stock price is 432% more volatile than the broader market. Comparatively, Traws Pharma has a beta of 1.51, meaning that its stock price is 51% more volatile than the broader market.

Traws Pharma has a consensus price target of $1.00, suggesting a potential upside of 63.67%. Given Traws Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Traws Pharma is more favorable than Direct Digital.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Direct Digital	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Traws Pharma	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60

4.0% of Direct Digital shares are held by institutional investors. Comparatively, 8.0% of Traws Pharma shares are held by institutional investors. 25.6% of Direct Digital shares are held by insiders. Comparatively, 7.6% of Traws Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Direct Digital beats Traws Pharma on 8 of the 15 factors compared between the two stocks.

How does Traws Pharma compare to Sol-Gel Technologies?

Sol-Gel Technologies (NASDAQ:SLGL) and Traws Pharma (NASDAQ:TRAW) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

26.2% of Sol-Gel Technologies shares are held by institutional investors. Comparatively, 8.0% of Traws Pharma shares are held by institutional investors. 66.5% of Sol-Gel Technologies shares are held by company insiders. Comparatively, 7.6% of Traws Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Sol-Gel Technologies had 3 more articles in the media than Traws Pharma. MarketBeat recorded 3 mentions for Sol-Gel Technologies and 0 mentions for Traws Pharma. Sol-Gel Technologies' average media sentiment score of 0.64 beat Traws Pharma's score of 0.00 indicating that Sol-Gel Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Sol-Gel Technologies	Positive
Traws Pharma	Neutral

Sol-Gel Technologies has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market. Comparatively, Traws Pharma has a beta of 1.51, meaning that its stock price is 51% more volatile than the broader market.

Sol-Gel Technologies currently has a consensus target price of $197.50, suggesting a potential upside of 123.74%. Traws Pharma has a consensus target price of $1.00, suggesting a potential upside of 63.67%. Given Sol-Gel Technologies' stronger consensus rating and higher possible upside, research analysts plainly believe Sol-Gel Technologies is more favorable than Traws Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Traws Pharma	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60

Traws Pharma has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -5.66%. Sol-Gel Technologies' return on equity of -3.17% beat Traws Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sol-Gel Technologies	-5.66%	-3.17%	-2.58%
Traws Pharma	N/A	-913.18%	-133.88%

Traws Pharma has lower revenue, but higher earnings than Sol-Gel Technologies. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sol-Gel Technologies	$18.47M	13.43	-$6.13M	-$0.34	N/A
Traws Pharma	$2.79M	3.32	$9.17M	-$1.69	N/A

Summary

Sol-Gel Technologies beats Traws Pharma on 13 of the 17 factors compared between the two stocks.

How does Traws Pharma compare to PDS Biotechnology?

Traws Pharma (NASDAQ:TRAW) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk.

PDS Biotechnology's return on equity of -346.02% beat Traws Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Traws Pharma	N/A	-913.18%	-133.88%
PDS Biotechnology	N/A	-346.02%	-102.36%

8.0% of Traws Pharma shares are held by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are held by institutional investors. 7.6% of Traws Pharma shares are held by insiders. Comparatively, 8.4% of PDS Biotechnology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Traws Pharma has higher revenue and earnings than PDS Biotechnology. PDS Biotechnology is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Traws Pharma	$2.79M	3.32	$9.17M	-$1.69	N/A
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.67	N/A

In the previous week, Traws Pharma's average media sentiment score of 0.00 equaled PDS Biotechnology'saverage media sentiment score.

Company	Overall Sentiment
Traws Pharma	Neutral
PDS Biotechnology	Neutral

Traws Pharma presently has a consensus target price of $1.00, suggesting a potential upside of 63.67%. PDS Biotechnology has a consensus target price of $9.00, suggesting a potential upside of 1,087.34%. Given PDS Biotechnology's stronger consensus rating and higher probable upside, analysts clearly believe PDS Biotechnology is more favorable than Traws Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Traws Pharma	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Traws Pharma has a beta of 1.51, indicating that its share price is 51% more volatile than the broader market. Comparatively, PDS Biotechnology has a beta of 1.59, indicating that its share price is 59% more volatile than the broader market.

Summary

PDS Biotechnology beats Traws Pharma on 9 of the 12 factors compared between the two stocks.

How does Traws Pharma compare to CervoMed?

CervoMed (NASDAQ:CRVO) and Traws Pharma (NASDAQ:TRAW) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings and dividends.

25.2% of CervoMed shares are owned by institutional investors. Comparatively, 8.0% of Traws Pharma shares are owned by institutional investors. 35.8% of CervoMed shares are owned by insiders. Comparatively, 7.6% of Traws Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Traws Pharma has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. CervoMed's return on equity of -136.08% beat Traws Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CervoMed	-672.80%	-136.08%	-112.62%
Traws Pharma	N/A	-913.18%	-133.88%

In the previous week, CervoMed had 2 more articles in the media than Traws Pharma. MarketBeat recorded 2 mentions for CervoMed and 0 mentions for Traws Pharma. CervoMed's average media sentiment score of 0.00 equaled Traws Pharma'saverage media sentiment score.

Company	Overall Sentiment
CervoMed	Neutral
Traws Pharma	Neutral

CervoMed has a beta of -0.68, indicating that its stock price is 168% less volatile than the broader market. Comparatively, Traws Pharma has a beta of 1.51, indicating that its stock price is 51% more volatile than the broader market.

Traws Pharma has lower revenue, but higher earnings than CervoMed. CervoMed is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CervoMed	$4.01M	9.76	-$26.97M	-$3.28	N/A
Traws Pharma	$2.79M	3.32	$9.17M	-$1.69	N/A

CervoMed presently has a consensus target price of $22.60, indicating a potential upside of 680.93%. Traws Pharma has a consensus target price of $1.00, indicating a potential upside of 63.67%. Given CervoMed's stronger consensus rating and higher probable upside, research analysts plainly believe CervoMed is more favorable than Traws Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CervoMed	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Traws Pharma	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60

Summary

CervoMed beats Traws Pharma on 10 of the 15 factors compared between the two stocks.

How does Traws Pharma compare to Actuate Therapeutics?

Traws Pharma (NASDAQ:TRAW) and Actuate Therapeutics (NASDAQ:ACTU) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings, media sentiment and valuation.

In the previous week, Traws Pharma's average media sentiment score of 0.00 equaled Actuate Therapeutics'average media sentiment score.

Company	Overall Sentiment
Traws Pharma	Neutral
Actuate Therapeutics	Neutral

Traws Pharma has a beta of 1.51, meaning that its stock price is 51% more volatile than the broader market. Comparatively, Actuate Therapeutics has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market.

Traws Pharma has higher revenue and earnings than Actuate Therapeutics. Actuate Therapeutics is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Traws Pharma	$2.79M	3.32	$9.17M	-$1.69	N/A
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.97	N/A

8.0% of Traws Pharma shares are held by institutional investors. 7.6% of Traws Pharma shares are held by company insiders. Comparatively, 58.0% of Actuate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Traws Pharma presently has a consensus target price of $1.00, indicating a potential upside of 63.67%. Actuate Therapeutics has a consensus target price of $17.50, indicating a potential upside of 1,185.82%. Given Actuate Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Actuate Therapeutics is more favorable than Traws Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Traws Pharma	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Actuate Therapeutics' return on equity of -430.93% beat Traws Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Traws Pharma	N/A	-913.18%	-133.88%
Actuate Therapeutics	N/A	-430.93%	-180.86%

Summary

Traws Pharma and Actuate Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

Get Traws Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRAW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TRAW vs. The Competition

Export

Metric	Traws Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$9.26M	$3.08B	$6.80B	$12.44B
Dividend Yield	N/A	2.05%	2.67%	9.39%
P/E Ratio	-0.36	20.11	27.00	24.19
Price / Sales	3.32	344.93	518.66	94.29
Price / Cash	0.88	27.11	26.68	47.25
Price / Book	-8.73	4.27	10.68	6.26
Net Income	$9.17M	$65.94M	$3.59B	$331.52M
7 Day Performance	-13.31%	-1.50%	-0.19%	-1.19%
1 Month Performance	-28.14%	0.12%	1.93%	-1.35%
1 Year Performance	-62.74%	17.43%	25.24%	18.74%

Traws Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TRAW Traws Pharma	2.2837 of 5 stars	$0.61 +0.4%	$1.00 +63.1%	-61.8%	$9.29M	$2.79M	N/A	17
DRCT Direct Digital	1.1873 of 5 stars	$2.58 +0.4%	N/A	-97.8%	$1.91M	$34.69M	N/A	60	Gap Up
SLGL Sol-Gel Technologies	4.0896 of 5 stars	$77.21 +2.4%	$197.50 +155.8%	+881.6%	$211.84M	$19.39M	N/A	50	Analyst Forecast
PDSB PDS Biotechnology	2.4528 of 5 stars	$0.75 -0.8%	$9.00 +1,106.4%	-37.6%	$42.05M	N/A	N/A	20
CRVO CervoMed	2.8923 of 5 stars	$3.07 -0.3%	$22.60 +636.2%	-62.3%	$41.66M	$4.01M	N/A	4

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TRAW) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Traws Pharma (TRAW) Competitors

TRAW vs. DRCT, SLGL, PDSB, CRVO, and ACTU

How does Traws Pharma compare to Direct Digital?

Summary

How does Traws Pharma compare to Sol-Gel Technologies?

Summary

How does Traws Pharma compare to PDS Biotechnology?

Summary

How does Traws Pharma compare to CervoMed?

Summary

How does Traws Pharma compare to Actuate Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRAW vs. The Competition

Traws Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Traws Pharma (TRAW) Competitors

TRAW vs. DRCT, SLGL, PDSB, CRVO, and ACTU

How does Traws Pharma compare to Direct Digital?

Which has stronger earnings & valuation, DRCT or TRAW?

Does the media prefer DRCT or TRAW?

Is DRCT or TRAW more profitable?

Which has more risk & volatility, DRCT or TRAW?

Do analysts prefer DRCT or TRAW?

Do insiders & institutionals hold more shares of DRCT or TRAW?

Summary

How does Traws Pharma compare to Sol-Gel Technologies?

Do institutionals & insiders believe in SLGL or TRAW?

Does the media prefer SLGL or TRAW?

Which has more volatility and risk, SLGL or TRAW?

Do analysts rate SLGL or TRAW?

Is SLGL or TRAW more profitable?

Which has stronger earnings and valuation, SLGL or TRAW?

Summary

How does Traws Pharma compare to PDS Biotechnology?

Is TRAW or PDSB more profitable?

Do insiders and institutionals hold more shares of TRAW or PDSB?

Which has higher valuation and earnings, TRAW or PDSB?

Does the media refer more to TRAW or PDSB?

Do analysts recommend TRAW or PDSB?

Which has more risk & volatility, TRAW or PDSB?

Summary

How does Traws Pharma compare to CervoMed?

Do insiders & institutionals have more ownership in CRVO or TRAW?

Is CRVO or TRAW more profitable?

Does the media refer more to CRVO or TRAW?

Which has more volatility and risk, CRVO or TRAW?

Which has higher earnings and valuation, CRVO or TRAW?

Do analysts recommend CRVO or TRAW?

Summary

How does Traws Pharma compare to Actuate Therapeutics?

Does the media favor TRAW or ACTU?

Which has more volatility and risk, TRAW or ACTU?

Which has preferable valuation & earnings, TRAW or ACTU?

Do insiders and institutionals believe in TRAW or ACTU?

Do analysts prefer TRAW or ACTU?

Is TRAW or ACTU more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRAW vs. The Competition

Traws Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools